# Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer

> **NCT03828799** · PHASE1,PHASE2 · COMPLETED · sponsor: **Institut du Cancer de Montpellier - Val d'Aurelle** · enrollment: 13 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **COMBINATION_PRODUCT:** Folfirinox + regorafenib

## Key facts

- **NCT ID:** NCT03828799
- **Lead sponsor:** Institut du Cancer de Montpellier - Val d'Aurelle
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-14
- **Primary completion:** 2021-12-02
- **Final completion:** 2024-11-30
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03828799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03828799, "Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT03828799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*